References
- Adachi K, Suemizu H, Murayama N, et al. (2015). Human biofluid concentrations of mono(2-ethylhexyl)phthalate extrapolated from pharmacokinetics in chimeric mice with humanized liver administered with di(2-ethylhexyl)phthalate and physiologically based pharmacokinetic modeling. Environ Toxicol Pharmacol 39:1067–73
- Berry LM, Li C, Zhao Z. (2011). Species differences in distribution and prediction of human V(ss) from preclinical data. Drug Metab Dispos 39:2103–16
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
- Hasegawa M, Kawai K, Mitsui T, et al. (2011). The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 405:405–10
- Koyanagi T, Nakanishi Y, Murayama N, et al. (2015). Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole, and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. Xenobiotica 45:312–21
- Miyaguchi T, Suemizu H, Shimizu M, et al. (2015). Human urine and plasma concentrations of bisphenol A extrapolated from pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and semi-physiological pharmacokinetic modeling. Regul Toxicol Pharmacol 72:71–6
- Mogi M, Toda A, Iwasaki K, et al. (2012). Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. J Toxicol Sci 37:1157–64
- Nishiyama S, Suemizu H, Shibata N, et al. (2015). Simulation of human plasma concentrations of thalidomide and primary 5-hydroxylated metabolites explored with pharmacokinetic data in humanized TK-NOG mice. Chem Res Toxicol 28:2088–90
- Poulin P, Jones RD, Jones HM, et al. (2011). PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci 100:4127–57
- Rendic S, Guengerich FP. (2012). Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol 25:1316–83
- Shida S, Utoh M, Murayama N, et al. (2015). Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Xenobiotica 45:881–6
- Shida S, Yamazaki H. (2015). Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling. Xenobiotica. [Epub ahead of print]. DOI:10.3109/00498254.2015.1118650.
- Turpault S, Brian W, Van HR, et al. (2009). Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol 68:928–35
- Uehara S, Inoue T, Utoh M, et al. (2016). Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol, and midazolam, in common marmosets (Callithrix jacchus). Xenobiotica 46:163–8
- Yamazaki H, Suemizu H, Murayama N, et al. (2013). In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice. Chem Res Toxicol 26:486–9
- Yamazaki H, Suemizu H, Shimizu M, et al. (2012). In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice. Chem Res Toxicol 25:274–6